$1.33
-0.02-1.48%
Last update: Oct 23, 7:27 PM
Palisade Bio Inc (PALI) Stock Price, Quote, News & History
PALINASDAQ
Palisade Bio progresses its Phase 1 study for PALI-2108, showing safety and targeted bioactivation, with topline data anticipated in early 2025.
You can purchase shares of Palisade Bio (NASDAQ:PALI) through any online brokerage.
Other companies in Palisade Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Palisade Bio has a consensus price target of $10.10.
The stock price for Palisade Bio (NASDAQ: PALI) is $1.3 last updated October 23, 2026 at 7:27 PM EDT.
There are no upcoming dividends for Palisade Bio.
Palisade Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Palisade Bio.
Palisade Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and...
